Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2025

Congress Details

calander17-20 May 2025 | Serbia

locationBelgrade, Serbia

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

Cardiomyopathy-Analysis
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial
Cardiomyopathy-AReal
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan
hATTR-Patients
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program
Vutrisiran-in-Patients
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis

Associated Materials

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00167
hfsa-congress-usa-mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

26-29 September 2025 USA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00106
eu-attr-italy-mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

25-26 September 2025 ITALY

View Details
Preparation Date
March 2026
Job Code
MB-UK-00113
European Society of Cardiology (ESC) 2025 Congress, Spain

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

29 August - 1 September 2025 SPAIN

View Details
Preparation Date
March 2026
Job Code
MB-UK-00118

Transthyretin Amyloidosis (ATTR)

Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry

June 2025

Preparation Date
March 2026
Job Code
MB-UK-00168
Peripheral Nerve Society (PNS) 2025 Congress, UK

Transthyretin Amyloidosis (ATTR)

Peripheral Nerve Society (PNS) 2025

17-20 May 2025 UK

View Details
Preparation Date
March 2026
Job Code
MB-UK-00130
Preparation Date
March 2026
Job Code
MB-UK-00127